News

/News

Poseida Therapeutics Presents Novel BCMA-Specific CAR-T Therapy at CAR-TCR Summit

SAN DIEGO, September 6th, 2017 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving cell therapies, today presented preclinical data on P-BCMA-101, the company’s BCMA-specific CAR-T drug candidate for the treatment of multiple myeloma, at the CAR-TCR Summit on T Cell Immunotherapies in Boston. SAN DIEGO, September 6th, 2017 […]

By |September 6th, 2017|News|Comments Off on Poseida Therapeutics Presents Novel BCMA-Specific CAR-T Therapy at CAR-TCR Summit

Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor” CAR-T Cells at American Society of Clinical Oncology Annual Meeting

SAN DIEGO, June 5, 2017 – Poseida Therapeutics, Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced preclinical data demonstrating the use of the company’s proprietary high-fidelity genome editing system, NextGEN™ CRISPR, for production of allogeneic “universal donor” chimeric antigen receptor  T-cells (CAR-T). In a study presented today […]

By |June 5th, 2017|News|Comments Off on Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor” CAR-T Cells at American Society of Clinical Oncology Annual Meeting

Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy

MENLO PARK, Calif. and SAN DIEGO, May 22, 2017 (GLOBE NEWSWIRE) — Teneobio, Inc. and Poseida Therapeutics, Inc. today announced that they have entered a commercial license agreement for the use of Teneobio’s UniDabs™, single-domain, human heavy chain only antibodies in Chimeric Antigen Receptor (CAR) T-cell therapy. Under the terms of the agreement Poseida […]

By |May 22nd, 2017|News|Comments Off on Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy

Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual Meeting

SAN DIEGO, April 4, 2017 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced preclinical data from the company’s B-cell maturation antigen (BCMA)-specific chimeric antigen receptor CAR T-cell (CAR-T) drug candidate, referred to as P-BCMA-101. Data demonstrated potent and persistent anti-tumor activity, elimination of tumors […]

By |April 4th, 2017|News|Comments Off on Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual Meeting

Poseida Therapeutics Appoints Debra Gessner as Vice President, Regulatory Affairs

SAN DIEGO, Jan. 3, 2017 — Poseida Therapeutics Inc., a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced that Debra Gessner has joined the company as vice president, regulatory affairs.

Ms. Gessner brings deep expertise in drug development, regulatory communications and strategy — including significant experience in gene therapy and immuno-oncology […]

By |January 3rd, 2017|News|Comments Off on Poseida Therapeutics Appoints Debra Gessner as Vice President, Regulatory Affairs

Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at American Society of Hematology Annual Meeting

SAN DIEGO, December 5, 2016 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced preclinical data from the company’s B-cell maturation antigen (BCMA) specific chimeric antigen receptor (CAR) T-cell drug candidate, referred to as P-BCMA-101. Data demonstrated a superior stem cell memory phenotype and self-renewal […]

By |December 5th, 2016|News|Comments Off on Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at American Society of Hematology Annual Meeting

Poseida Therapeutics to Present Three Abstracts on Novel BCMA-Specific CAR-T Therapy at American Society of Hematology 2016 Annual Meeting

SAN DIEGO, November 3, 2016 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced that three abstracts detailing preclinical data on P-BCMA-101, the company’s BCMA-specific CAR-T drug candidate, have been selected for presentation at the American Society of Hematology (ASH) Annual Meeting. The studies explore […]

By |November 3rd, 2016|News|Comments Off on Poseida Therapeutics to Present Three Abstracts on Novel BCMA-Specific CAR-T Therapy at American Society of Hematology 2016 Annual Meeting

Poseida Therapeutics Establishes Scientific Advisory Board

SAN DIEGO, California – September 08, 2016 – Poseida Therapeutics, Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, announced the creation of the company’s scientific advisory board with several key appointments. The scientific advisory board will provide guidance on the application of Poseida’s gene editing technology platform towards the […]

By |September 8th, 2016|News|Comments Off on Poseida Therapeutics Establishes Scientific Advisory Board

Poseida Therapeutics Expands Executive Leadership Team

SAN DIEGO, California – August 18, 2016 – Poseida Therapeutics, Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, announced the expansion of the company’s executive team with several key appointments.  Matthew Spear, M.D., has been appointed Chief Medical Officer, Ryan Takeya has been appointed Vice President, Technical Operations, and […]

By |August 18th, 2016|News|Comments Off on Poseida Therapeutics Expands Executive Leadership Team

Poseida Therapeutics Announces Series A Financing

La Jolla, CA, December 16, 2015: Poseida Therapeutics, Inc. (“Poseida”), a US-based, privately-held, human therapeutics company focused on the development of novel therapies using its ground-breaking proprietary genome engineering technologies, today announced that it has closed a Series A Preferred Stock financing. The lead investor, Malin Corporation plc. (“Malin”), an Irish-based global life sciences company, has agreed […]

By |December 16th, 2015|News|Comments Off on Poseida Therapeutics Announces Series A Financing